The most successful pharmaceutical launches don’t begin at approval. They begin when there’s still time to identify, and engineer out, preventable risk.
By the time a therapy reaches Phase III clinical trials, it has progressed through years of clinical research conducted under internationally recognized Good Clinical Practice (GCP) standards to establish its safety, efficacy, and quality.
But clinical readiness and real-world readiness are not the same thing.
Once a therapy moves beyond the controlled environment of a clinical trial, patients, healthcare professionals (HCPs), caregivers, and support teams must navigate an entirely different set of challenges: access, onboarding, education, safety requirements, administration, adherence, monitoring, and ongoing support.
For high-cost, high-complexity therapies, those challenges carry significant consequences. A missed step in onboarding, a breakdown in communication, or an avoidable lapse in adherence can affect patient outcomes, create safety concerns, and undermine the substantial investment required to bring a therapy to market.
That is why launch readiness needs to begin well before approval.
McKinsey notes that planning and executing a pharmaceutical launch typically takes three to four years, with strategic planning beginning well before approval and transitioning to country-level execution in the 18 months leading up to launch.
The strongest launch teams use that time to prepare for launch day and build the infrastructure required to support a therapy in the real world.
Explore RxPx Therapy Infrastructure
Launch success starts with understanding where therapy risk lives
A successful pharmaceutical launch is about more than bringing a medicine to market. It is about creating the conditions for the right patients to access therapy, initiate successfully, and remain safely and appropriately supported throughout treatment.
As pharmaceutical launches become increasingly complex, leading organizations are shifting from product-centric strategies to customer-centric approaches that prioritize the experiences of patients and HCPs throughout the treatment journey.
For teams preparing to launch a complex therapy, this means identifying where risk can emerge:
- Where could patients encounter friction before starting therapy?
- What education and support will HCPs need to prescribe and manage the therapy confidently?
- Where are patients most likely to disengage or become non-adherent?
- Which handoffs between patients, HCPs, and support services could fail?
- What data will teams need to identify problems early?
- How will support scale without sacrificing quality, safety, or personalization?
These questions are particularly important for high-cost, complex therapies, where the consequences of preventable failure can be severe.
Patients may struggle with complicated treatment protocols. HCPs may require additional education. Support may be fragmented across vendors and channels. Critical information may not reach the right person at the right time.
McKinsey’s research shows that organizations designing launches around the patient journey, rather than the product alone, create stronger customer experiences and better commercial outcomes.
Instead of asking, “How do we launch this medicine?” teams should also ask, “What needs to be in place for this therapy to succeed safely in the real world?”
Explore RxPx End-to-End Services
Build the infrastructure around the therapy
Starting early gives pharmaceutical companies the opportunity to identify potential failure points before they affect patients or become difficult and costly to change.
This is especially important for therapies with complex administration requirements, significant safety considerations, challenging adherence journeys, or substantial costs associated with initiation and discontinuation.
Effective pre-launch planning can include:
- Mapping the patient and HCP journey.
- Identifying high-risk moments and preventable points of failure.
- Understanding HCP education and workflow requirements.
- Designing connected patient support.
- Embedding safety, regulatory, and compliance requirements.
- Connecting digital engagement with appropriate human intervention.
- Establishing the data infrastructure required for visibility and real-world evidence.
The objective isn’t simply to have a patient program ready by launch. It is to create a support system capable of carrying the therapy from prescription through initiation, persistence, and long-term management.
According to IQVIA, launch excellence depends on early cross-functional planning, stakeholder alignment, and data-driven decision-making – not simply flawless execution after approval.
Technology should support the strategy, not define it
AI and digital health are creating new opportunities across pharmaceutical commercialization and patient support.
Predictive analytics can help identify patients who may need additional support. Personalized education can deliver relevant information at critical moments. Automation can make engagement more scalable and consistent.
But adding technology to a fragmented patient journey does not make that journey connected.
For complex therapies, technology needs to operate as part of a broader infrastructure that brings together therapy and patient journey expertise, behavioral science, AI-enabled technology, human intervention, real-world insights, and continuous optimization.
AI can help identify signals, personalize experiences, and determine when intervention may be needed. Human expertise remains essential when context, empathy, safety, or escalation require judgment.
The goal isn’t more technology. It’s the right infrastructure around the therapy.
Explore RxPx Technology
Why infrastructure decisions need to happen before approval
One of the most expensive mistakes launch teams can make is treating patient support infrastructure as a downstream implementation decision.
By the time approval is approaching, vendors may have been selected, workflows defined, data architecture established, and patient programs scoped. At that point, teams may be optimizing around decisions that have already been made rather than designing the right system from the beginning.
Starting earlier creates room to ask more fundamental questions:
- Does the support model reflect how patients will actually experience the therapy?
- Can it accommodate the regulatory and safety requirements of the product?
- Can teams identify when patients are struggling?
- Are digital and human support connected?
- Can the infrastructure adapt as evidence and patient needs evolve?
And, critically, where could a preventable failure have the greatest clinical, operational, or commercial consequence?
These aren’t simply technology questions. They’re infrastructure questions.
Complex therapies require more than a contractor
For straightforward programs, it may be enough to define requirements and hire a vendor to execute them.
High-complexity therapies demand something different.
When regulatory, safety, and adherence stakes are high, pharmaceutical teams need a partner that can help identify risks, challenge assumptions, and design the infrastructure around the therapy – not simply build what has already been specified.
The distinction matters.
A contractor delivers a brief.
An infrastructure partner helps determine what needs to be built, why it matters, and where the greatest risks need to be addressed before they become expensive problems.
At RxPx, we specialize in the therapies where getting that infrastructure right matters most. We bring together therapy strategy, behavioral science, AI-enabled technology, human expertise, and real-world insights to design and operate connected support around complex therapies.
Because when the cost of a preventable failure is high, the infrastructure supporting the therapy can’t be an afterthought.
Book a Therapy Risk Assessment
Every complex therapy has points of vulnerability.
The important question is whether you identify them while there’s still time to do something about them.
A Therapy Risk Assessment helps your team identify potential risks across the patient and HCP journey, examine the infrastructure required to support the therapy, and uncover opportunities to reduce preventable failure before launch.
Whether you’re approaching Phase III, preparing for regulatory submission, or building your commercialization strategy, starting earlier gives you more options.
Book a Therapy Risk Assessment and identify where your therapy may be exposed before those risks reach the real world.
